ELTX
Elicio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.41
−3.60%Jul 2, 2026, 04:25 UTC
Elicio Therapeutics priced a registered direct offering of 4,380,313 shares of common stock for gross proceeds of approximately $15 million.
Jun 17, 2026, 16:43 UTC
Elicio Therapeutics reported clinical observations for its ELI-002 7P cancer drug, indicating durable responses.
Source:Jun 15, 2026, 13:58 UTC
Elicio Therapeutics shares fell about 73% in early trading on Monday after its pancreatic cancer therapy failed a mid-stage study.
Source: